Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.

Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Abstract Text:

Hong Wang,Haiyong Han,Daniel D Von Hoff,

One of the most common types of genetic alterations in cancer is the loss-of-function mutations in tumor-suppressor genes. Such mutations are usually very specific to cancer cells and present attractive and unique opportunities for therapeutic interventions. However, for various reasons, antitumor agents that target loss-of-function mutations have not been readily identified. In this report, using the deleted in pancreatic cancer locus 4 (DPC4) gene in pancreatic cancer as an example, we show the feasibility of a novel screening strategy, which we have named Pharmacological Synthetic Lethal Screening, for the identification of agents that selectively target cancer cells with loss-of-function mutations. We created DPC4 isogenic cell lines through the restoration of wild-type DPC4 in a pancreatic cancer cell line, BxPC-3, whose DPC4 gene was homozygously deleted. The isogenic cell lines were then used in the Pharmacological Synthetic Lethal Screening to evaluate compound libraries for antiproliferative activity and selectivity against DPC4 deficiency. After screening 19,590 compounds, we identified one lead compound, UA62001, which showed 4.6-fold selectivity against DPC4 deficiency in the DPC4 isogenic cell lines. UA62001 selectivity was also seen in another set of DPC4 isogenic cell lines generated by small interfering RNA knockdown. In addition, UA62001 was evaluated in commonly used pancreatic cancer cell lines. A fairly good correlation between DPC4 deficiency and UA62001 sensitivity was observed. Cell cycle analysis indicates that UA62001 arrests cells in S and G(2)-M phases. The results of microarray gene expression profiling and quantitative real-time reverse transcription-PCR suggest that cyclin B/CDC2 and minichromosome maintenance complexes might be the downstream cellular targets of UA62001.

Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Publishing Authors By Initials

H Wang,H Han,DD Von Hoff,

For similar peptides: intracellular signaling peptides and proteins: adaptor proteins, signal transducing: smad proteins: smad4 protein research abstracts see: peptides: intracellular signaling peptides and proteins: adaptor proteins, signal transducing: smad proteins: smad4 protein research

PUBMED ID PMID:

MEDLINE DATE:

Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Cancer research

VOLUME: 66

Page Numbers: 9722-30

Journal Abbreviation: Cancer Res.

ISSN: 1538-7445

DAY: 1

MONTH: Oct

YEAR: 2006

Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2984705

Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Keywords Mesh Terms:

KEYWORDS: Smad4 Protein

MESH TERMS: genetics

Chemical & Substance for Abstract: Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Information

Substance Name: CDC2 Protein Kinase

Registry Number: EC 2.7.1.37

Grant and Affiliation Information for Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.

AFFILIATION: Pancreatic Cancer Research Laboratory, Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA. hwang@tgen.org

Country: United States

AGENCY: United States NCI

GRANT: P01 CA109552

ACRONYM: CA

MEDLINETA: Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Identification of an agent selectively targeting DPC4 deleted in pancreatic cancer locus 4-deficient pancreatic cancer cells Related Publications

• A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.
• A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.
• Aurora sheds light on head and neck squamous cell carcinoma.
• Evaluation and role of single chemotherapeutic agents in adult non-Hodgkin's lymphoma.
• Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.
• In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors.
• Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.
• Phase II Study of Azacitidine to Restore Responsiveness of Prostate Cancer to Hormonal Therapy.
• Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells.
• Tubulin-associated Proteins: Aurora and Polo-like Kinases as Therapeutic Targets in Cancer.
• Tumor-stroma interactions in pancreatic ductal adenocarcinoma.